Dr. Schmoll on the Toxicity of the CHARTA Study in CRC

Hans-Joachim Schmoll, MD
Published: Tuesday, Oct 10, 2017



Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).

According to Schmoll, every patient with CRC who needs chemotherapy should receive FOLFOX and bevacizumab (Avastin) with irinotecan.

Overall, the toxicity of the combination was well tolerated. Additionally, there was no significant difference in the quality of life between both arms.
 
SELECTED
LANGUAGE


Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).

According to Schmoll, every patient with CRC who needs chemotherapy should receive FOLFOX and bevacizumab (Avastin) with irinotecan.

Overall, the toxicity of the combination was well tolerated. Additionally, there was no significant difference in the quality of life between both arms.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x